Bristol Myers Squibb Company $BMY Shares Sold by RNC Capital Management LLC

Key Points

• RNC Capital Management LLC cut its stake in Bristol Myers Squibb by 7.0% in Q4, selling 46,351 shares and leaving it with 616,326 shares valued at about $33.25 million.
• Bristol Myers Squibb beat quarterly estimates, reporting $1.58 EPS vs. $1.42 expected and $11.49 billion in revenue, and set FY2026 guidance of $6.05–$6.35 EPS (consensus ~6.29).
• The company recently paid a quarterly dividend of $0.63 (annualized $2.52), representing a 4.4% yield and a payout ratio of roughly 70.8%.

RNC Capital Management LLC decreased its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 7.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 616,326 shares of the biopharmaceutical company's stock after selling 46,351 shares during the quarter. RNC Capital Management LLC's holdings in Bristol Myers Squibb were worth $33,245,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in BMY. Novem Group increased its position in Bristol Myers Squibb by 2.9% during the 4th quarter. Novem Group now owns 6,402 shares of the biopharmaceutical company's stock worth $345,000 after purchasing an additional 183 shares in the last quarter. Dominguez Wealth Management Solutions Inc. increased its holdings in Bristol Myers Squibb by 0.8% in the 4th quarter. Dominguez Wealth Management Solutions Inc. now owns 22,404 shares of the biopharmaceutical company's stock valued at $1,208,000 after purchasing an additional 185 shares in the last quarter. McLean Asset Management Corp increased its holdings in Bristol Myers Squibb by 3.1% in the 4th quarter. McLean Asset Management Corp now owns 6,465 shares of the biopharmaceutical company's stock valued at $369,000 after purchasing an additional 192 shares in the last quarter. Bath Savings Trust Co increased its holdings in Bristol Myers Squibb by 2.3% in the 4th quarter. Bath Savings Trust Co now owns 8,743 shares of the biopharmaceutical company's stock valued at $472,000 after purchasing an additional 198 shares in the last quarter. Finally, Traub Capital Management LLC increased its holdings in Bristol Myers Squibb by 2.0% in the 4th quarter. Traub Capital Management LLC now owns 10,228 shares of the biopharmaceutical company's stock valued at $552,000 after purchasing an additional 200 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company's stock.

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $57.36 on Tuesday. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. The business has a 50 day moving average of $59.56 and a two-hundred day moving average of $54.63. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $62.89. The company has a market cap of $117.11 billion, a P/E ratio of 16.11, a PEG ratio of 0.17 and a beta of 0.26.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating analysts' consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The company had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. During the same period in the previous year, the firm posted $1.80 earnings per share. Bristol Myers Squibb's quarterly revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, analysts anticipate that Bristol Myers Squibb Company will post 6.29 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd were issued a dividend of $0.63 per share. The ex-dividend date of this dividend was Thursday, April 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.4%. Bristol Myers Squibb's payout ratio is 70.79%.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Leerink Partners raised their target price on Bristol Myers Squibb from $54.00 to $60.00 and gave the company an "outperform" rating in a research note on Tuesday, January 13th. Royal Bank Of Canada started coverage on shares of Bristol Myers Squibb in a research report on Tuesday, February 24th. They set a "sector perform" rating and a $60.00 price target for the company. Weiss Ratings reissued a "hold (c)" rating on shares of Bristol Myers Squibb in a research report on Monday, March 23rd. Bank of America decreased their price target on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a "buy" rating for the company in a research report on Thursday, April 9th. Finally, Barclays started coverage on shares of Bristol Myers Squibb in a research report on Thursday, February 19th. They set an "overweight" rating and a $75.00 price target for the company. Eight analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Bristol Myers Squibb presently has a consensus rating of "Hold" and a consensus target price of $61.31.

Insider Activity

In other news, EVP David V. Elkins sold 30,000 shares of the business's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the transaction, the executive vice president owned 159,248 shares of the company's stock, valued at approximately $9,820,824.16. The trade was a 15.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.05% of the company's stock.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.